This study is randomized, controlled, parallel, prospective clinical study will be conducted
on 60 patients diagnosed with type 2 diabetes mellitus at least five years ago. Patients will
be recruited from Tanta University Hospital, Tanta, Egypt.
Accepted patients will be randomized into 2 groups as the following:
Control group: 30 patients will receive maximum tolerated dose of ACEI plus placebo pills for
six months Treatment group: 30 patients will receive maximum tolerated dose of ACEI plus
niclosamide tablets 1 gram once daily for six months The primary end point will be the change
in Urinary albumin to creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR)
after six months of treatment